


REPUBLIQUE TUNISIENNE
Ministère De la Recherche Scientifique
De la Technologie et du Développement des Compétences
Centre de Biotechnologie de Sfax
ADM/T.A/Réf. M.S.Y.../2005/CBS



Sfax, 19 th September 2005

Prof. Hammadi Ayadi, Director of the Centre of biotechnology of Sfax
Prof. Samir BEJAR, Scientific Responsible of the US Patent Number 6372 476

To

United States Patent and Trademark Office

Object: Registration fees of US Patent 6372476

Dear Sir,

We would like to inform you that the US Patent N° 6,372,476 was deposit with the Centre of Biotechnology of Sfax-Tunisia as inventors and Novozymes as applicant. Actually, Novozymes was sent a letter (copy enclosing) where they explain that they would like to abandon this US patent. In that event and according to the agreement between Novozymes and CBS of 12 November 1999, CBS will have the right to become owner of the issued patents and CBS shall pay full maintenance from the date when Novozymes chooses to abandon.

In order to taking over the patent, Would you be so kind to sent for the CBS an invoice in order to go on of the payment of the Patent Fees maintenance or explain how we can proceed for this payment?


Looking forward from you as soon as possible.

Best regards
Sincerely Yours

Prof. Hammadi Ayadi
Director of the CBS



Prof. Samir BEJAR
Scientific Responsible of the above
mentioned Patent



Copie to Dr. Henrik Bendiksen NOVOZYMES A/S Patents

BY FAX - 1 page

Centre de Biotechnologie de Sfax
Att.: Prof. Samir Bejar
BP "K" 3038 Sfax
TUNISIE

22 September 2004

Your ref:-
Our ref: 6004.200-US

URGENT

Dear Samir,


This is to inform you that Novozymes A/S intends to abandon US Patent No. 6,372,476 in the name of Novozymes A/S and relating to "Streptomyces "SK" Gl gene". The inventors of the patent are:

Karima Srih Belguith,
Radhouane Ellouz, and
Samir Bejar

In accordance with the Research Agreement between Novozymes and CBS dated 12 November 1999, Novozymes has the right to abandon any issued patents. However, in that event CBS will have the right to become owner of the issued patents and CBS shall pay full maintenance from the date when Novozymes chooses to abandon.

Please inform us before 1 November 2004 whether CBS intends to take over the above US patent. In the event that we do not hear from you in due course we will proceed with the abandonment procedure.

Yours sincerely
Novozymes A/S


Henrik Bendixsen,
Patents